Literature DB >> 7873470

Regression of left ventricular hypertrophy and improvement of renal hemodynamics in hypertensive patients treated with quinapril.

L De Caprio1, M L De Rosa, A Di Palma, C Lirato, P Caccese, M Sestito, S Lastoria, A M Cicatiello, F Rengo.   

Abstract

Of 17 patients with mild to moderate essential hypertension, 8 showed echocardiographic evidence of left ventricular hypertrophy. Cardiac and renal function evaluated by glomerular filtration rate (GFR) were studied in all patients before and after 20 weeks of quinapril treatment. Systolic pressure decreased from 174.7 +/- 16.7 to 131.7 +/- 7.7 mmHg (p < .0001) and diastolic pressure decreased from 101.8 +/- 9.8 to 80 +/- 4.3 mmHg (p < .0001). Left ventricular mass index decreased in the eight patients with left ventricular hypertrophy (p < .01). Basal values of GFR were lower than normal in 41% of all patients; GFR increased significantly after 20 weeks of treatment (from 96.5 +/- 32.3 to 108.6 +/- 31.12 ml/min, p < .01); it decreased in only one patient. Patients reported few adverse effects to quinapril, and no important clinical laboratory abnormality was observed. Quinapril not only lowered arterial pressure, but it had a distinct effect on regression of left ventricular hypertrophy and favorable effects on renal function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7873470     DOI: 10.1007/bf00877120

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  17 in total

1.  Quinapril--a new angiotensin-converting enzyme inhibitor: an overview.

Authors:  V I Dzau
Journal:  Angiology       Date:  1989-04       Impact factor: 3.619

2.  Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421.

Authors:  M L Cohen; K D Kurz
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

3.  Split renal function testing using Tc-99m DTPA. A rapid technique for determining differential glomerular filtration.

Authors:  G F Gates
Journal:  Clin Nucl Med       Date:  1983-09       Impact factor: 7.794

4.  Renal effects of angiotensin converting enzyme inhibitors in hypertension.

Authors:  J H Bauer; G P Reams
Journal:  Am J Med       Date:  1986-10-31       Impact factor: 4.965

5.  Recommendations for human blood pressure determination by sphygmomanometers.

Authors:  W M Kirkendall; A C Burton; F H Epstein; E D Freis
Journal:  Circulation       Date:  1967-12       Impact factor: 29.690

6.  Inhibition of angiotensin-converting enzyme with quinapril (CI-906): investigation of antihypertensive mechanisms in spontaneously hypertensive rats.

Authors:  P Säynävälammi; I Pörsti; A K Nurmi; E Seppälä; T Metsä-Ketelä; L Tuomisto; V Manninen; H Vapaatalo
Journal:  J Pharmacol Exp Ther       Date:  1986-04       Impact factor: 4.030

7.  Standardization of M-mode echocardiographic left ventricular anatomic measurements.

Authors:  R B Devereux; E M Lutas; P N Casale; P Kligfield; R R Eisenberg; I W Hammond; D H Miller; G Reis; M H Alderman; J H Laragh
Journal:  J Am Coll Cardiol       Date:  1984-12       Impact factor: 24.094

8.  Pathophysiologic assessment of hypertensive heart disease with echocardiography.

Authors:  F G Dunn; P Chandraratna; J G deCarvalho; L L Basta; E D Frohlich
Journal:  Am J Cardiol       Date:  1977-05-26       Impact factor: 2.778

9.  Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study.

Authors:  D Levy; D D Savage; R J Garrison; K M Anderson; W B Kannel; W P Castelli
Journal:  Am J Cardiol       Date:  1987-04-15       Impact factor: 2.778

Review 10.  Angiotensin converting enzyme inhibitors and renal function.

Authors:  A Mimran; J Ribstein
Journal:  J Hypertens Suppl       Date:  1989-09
View more
  1 in total

Review 1.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.